Metformin and Congenital Nephrogenic Diabetes Insipidus

Stopped early · Phase 1

Conditions studied: Diabetes Insipidus

In brief

The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).

Key facts

Study ID

NCT02460354

Run by

Emory University

People needed

2

Starts

2015-09-01

Expected to finish

2017-06-01

Last updated by the study team

2018-07-17

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Males with a documented mutation in the vasopressin type 2 receptor (V2R)
• Willing to provide consent and/or assent as appropriate
• Capable of providing urine samples as dictated by the protocol

You may not qualify if…

• Urinary incontinence
• Subjects who have heart disease, liver disease, diabetes, cancer, or other significant disease other than Nephrogenic Diabetes Insipidus (NDI)
• Subjects with significant renal dysfunction (defined as a calculated glomerular filtration rate (GFR) <80 ml/min/1.73 m\^2)
• Subjects with acquired NDI

Where it is running

• Childen's Healthcare of Atlanta — Atlanta, Georgia, United States
• Emory University Hospital - Atlanta Clinical and Translational Science Institute (ACTSI) — Atlanta, Georgia, United States
• Emory University Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.